Epidemiological, Basic Science and Clinical Research Studies in Heart Failure

Dear Colleagues,

Despite advances in cardiovascular disease diagnostics and therapies, the prevalence of heart failure continues to rise, and it currently affects 6.7 million adults in the US. Heart failure adversely impacts quality of life and is also a leading cause of hospital admissions, morbidity, and mortality. The financial costs attributed to heart failure are exorbitant and are expected to rise further and reach USD 69.8 billion by 2030. Consequently, it is necessary to conduct more studies focused on improving our knowledge on the pathophysiological mechanisms that drive heart failure and preventive strategies that can be implemented to ameliorate heart failure risk across diverse populations. A better understanding of the factors that underlie differential responses to established heart failure therapies, as well as the impact of social determinants of health on heart failure outcomes, is also necessary. This Special Issue will expand the published evidence on heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and advanced heart failure by calling for epidemiological, basic science, and clinical research studies that will evaluate the following:

1. The pathophysiological mechanisms that lead to heart failure, including the impact of racial/ethnic and gender differences;
2. Traditional and emerging risk factors for heart failure and how they can be modified to reduce future heart failure risk through pharmacologic and non-pharmacologic interventions;
3. Diverse types of cardiomyopathies that can result in heart failure, including, but not limited to, cardiac amyloidosis, hypertrophic cardiomyopathy, and sarcoidosis;
4. The impact of social determinants of health on heart failure outcomes;
5. Implementation science studies on the real-life effectiveness of heart failure interventions.

Dr. Imo A. Ebong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.